INHIBITORS OF SERINE PROTEASES
    11.
    发明专利

    公开(公告)号:NZ579295A

    公开(公告)日:2012-03-30

    申请号:NZ57929508

    申请日:2008-02-20

    Applicant: VERTEX PHARMA

    Abstract: Disclosed are spiro compounds of formula I or pharmaceutically acceptable salts thereof, and methods for their synthesis. Specific examples of compounds of formula I include: (5S,8S)-7-((S)-2-(2-cyclohexylacetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-2-oxo-3-phenyl-1-oxa-3,7-diazaspiro[4.4]nonane-8-carboxamide, (5R,8S)-7-((S)-2-(2-cyclohexylacetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-2-oxo-3-phenyl-1-oxa-3,7-diazaspiro[4.4]nonane-8-carboxamide, Cyclopentyl-(S)-1-((3S,5R)-3-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-ylcarbamoyl)-8-oxo-7-phenyl-2,7-diazaspiro[4.4]nonan-2-yl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate, and Cyclopentyl (S)-1-((3S,5S)-3-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-ylcarbamoyl)-8-oxo-7-phenyl-2,7-diazaspiro[4.4]nonan-2-yl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate. Also disclosed is the use of compounds of formula I for treating a hepatitis C virus (HCV) infection.

    INHIBIDORES DE SERINA PROTEASAS.
    16.
    发明专利

    公开(公告)号:MX2008001528A

    公开(公告)日:2008-04-04

    申请号:MX2008001528

    申请日:2006-08-01

    Applicant: VERTEX PHARMA

    Abstract: La invencion se refiere a compuestos de la formula (I): (ver formula) o una sal farmaceuticamente aceptable o mezclas de los mismos en donde C* representa un carbono diaestereomerico que comprende una mezcla de isomeros R y S en donde el isomero R es mayor al 50% de la mezcla.

    Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

    公开(公告)号:ZA200601420B

    公开(公告)日:2007-06-27

    申请号:ZA200601420

    申请日:2004-07-16

    Applicant: VERTEX PHARMA

    Abstract: The present invention relates to compounds of formula I or formula Ia or pharmaceutically acceptable salts thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.

Patent Agency Ranking